We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

25 Jun 2026 - 27 Jun 2026
02 Jul 2026 - 04 Jul 2026
08 Jul 2026 - 10 Jul 2026

Handheld Optical Device Screens for Early Necrotizing Enterocolitis in Preterm Infants

By HospiMedica International staff writers
Posted on 18 Jun 2026

Necrotizing enterocolitis (NEC) is a sudden, rapidly progressive intestinal disease of premature infants that can lead to sepsis, surgery, and death. More...

Clinicians struggle to recognize NEC at its earliest stages before damage becomes visible on imaging. Early identification could enable timely medical therapy and reduce operative risk. To help address this challenge, investigators have developed a noninvasive optical device to screen preterm infants for early signs of NEC.

Broadband optical spectroscopy (BOS) was developed at Ann & Robert H. Lurie Children’s Hospital of Chicago in collaboration with a biomedical engineering laboratory at Northwestern University. The handheld device is designed for bedside use in the neonatal intensive care unit. The first-in-human study reporting its clinical use has been published in the Journal of Pediatric Surgery. The technology aims to detect NEC earlier than radiography can.

The BOS probe is placed gently on the infant’s abdomen. It measures infrared light reflected from the intestines and analyzes spectral signatures for changes in color that surgeons recognize as indicative of threatened intestinal tissue in NEC. The assessment is completed within about two minutes and does not expose infants to pain or radiation.

In the initial clinical evaluation, investigators tested BOS in 96 premature infants who were younger than 36 weeks’ gestation. Infants with congenital cardiac conditions or abdominal wall defects were excluded. The study found that BOS was safe and feasible in this population and produced detectable signal changes in infants with NEC. The findings support further validation of BOS as a screening modality to identify earlier stages of disease, when antibiotic therapy may still be effective.

“Our results show that BOS is a safe and feasible technology that produced detectable signal changes in premature infants with NEC. These findings suggest that BOS is a promising and potentially groundbreaking modality for screening and early detection of NEC,” said Seth Goldstein, MD, MPhil, pediatric general and thoracic surgeon at Lurie Children’s and Associate Professor of Surgery at Northwestern University Feinberg School of Medicine.

Related Links
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Pediatric Mask
Respire SOFT
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.